SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to its potential for a short squeeze, fueled by a low float and high short interest, as well as its upcoming presentation at an emerging growth conference. Community members are actively discussing the company's shift towards AI and digital infrastructure, viewing it as undervalued compared to its peers, and anticipating potential catalysts from the conference. The stock's volatile price action and history of explosive moves are also contributing to the heightened interest.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to a mixed earnings report, with concerns arising from increased spending on AI infrastructure and rising debt despite strong cloud growth and a large backlog. Community discussions revolve around whether Oracle can effectively monetize its AI investments, with some questioning the long-term viability of its strategy, while others see a buying opportunity amid the selloff. The broader market is reacting, with some fearing a potential AI bubble burst.

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Rezolute Inc

Rezolute Inc is trending downwards following the announcement of failed phase 3 trials, leading to a significant drop in stock price and triggering disappointment among investors who had anticipated positive data. The community is discussing the potential reasons for the data miss, possible future actions for the company given its cash reserves, and whether a rebound is possible, while some traders are exploring potential shorting opportunities or bottom-fishing strategies.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending following news of a national retail distribution agreement with Walmart, causing significant premarket gains. The community is actively discussing potential price targets and whether the stock can sustain its momentum, while also considering potential resistance levels. This development marks AXIL's largest retail placement, expanding access to its hearing protection products.

iRobot Corp. is a robot company, which engages in designing and building robots. The firm's products include robot vacuums and maps, and pool cleaners. It operates through Domestic and International geographical segments. The company was founded by Rodney Allen Brooks, Colin M. Angle, and Helen Greiner in August 1990 and is headquartered in Bedford, MA.

Irobot Corp

iRobot Corp

IRBT is trending as traders discuss a potential short squeeze, citing very high short interest and recent price movement. Community members are pointing to the difficulty in borrowing shares and high borrowing fees as further indicators of a possible squeeze. Some are expressing caution, noting the company's fundamentals and potential for a bull trap.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a potential buyout and the company's recent progress in its DM1 clinical study. Community members are debating the stock's valuation, upcoming milestones, and the potential impact of competitor data, while also analyzing recent analyst ratings and institutional ownership.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending downwards amidst analyst downgrades, most recently from BofA and JP Morgan, with concerns stemming from slowing growth in branded checkout and a perceived lack of management confidence. The community is debating the impact of buybacks, the CEO's performance, and whether the stock is undervalued or a value trap. Some traders express frustration, while others see an opportunity for long-term gains if PayPal can turn things around.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a massive intraday price surge, fueled by its low float and significant volume, leading to discussions about potential short squeezes and comparisons to other recent high-flying stocks. The community is actively debating whether the run has ended or if there is potential for further gains, with some cautioning about bag holding and others anticipating after-hours momentum. Overall, traders are focused on the stock's volatile price action and potential for quick profits.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is trending as it approaches new lows, sparking discussions about its future and potential S&P 500 exclusion. The community is debating factors like competition from Amazon, tax-loss harvesting, and the CEO's performance amid the stock's significant year-to-date decline. Some investors see a buying opportunity, while others express concerns about the company's ability to compete and innovate.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as traders debate whether its S&P 500 inclusion justifies its high valuation, with some calling it a "scam" and others predicting further gains. Community discussions revolve around potential short squeezes, the influence of interest rate cuts, and concerns about the company's fundamentals versus market hype. Despite the debate, the stock's strong upward momentum has captured significant attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TuHURA Biosciences Provides Corporate Update Following Recent Financing

TuHURA Biosciences Provides Corporate Update Following Recent Financing TuHURA Biosciences Provides Corporate Update Following Recent Financing PR Newswire TAMPA, Fla., Dec. 11, 2025 Company's lead...

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering PR Newswire TAMPA, Fla., Dec. 9, 2025 TAMPA...

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and...

TuHURA Biosciences (NASDAQ:HURA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of TuHURA Biosciences from a "sell" rating to a "hold" rating in a report on Saturday...

TuHURA Biosciences (NASDAQ:HURA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday...

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Buy" from Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) has earned an average rating of "Buy" from the six analysts that are covering the company, Marketbeat reports. One investment analyst has...

TuHURA Biosciences (NASDAQ:HURA) Releases Earnings Results, Beats Estimates By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of...

TuHURA Biosciences (NASDAQ:HURA) Price Target Cut to $8.00 by Analysts at Maxim Group

Maxim Group decreased their price target on TuHURA Biosciences from $15.00 to $8.00 and set a "buy" rating for the company in a research note on Friday...

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate...

Shares of Tuhura Biosciences surged 20.2% in after-hours trading on Monday after the company and Kineta, Inc. said shareholders from both firms approved their proposed merger and all related proposals at special meetings held earlier in the day.The stock closed Monday's regular session slightly lower at $2.53, down 0.8%.The merger will combine Tuhura's clinical-stage immuno-oncology platform, including its Phase 3-ready lead asset IFx-2.0, with Kineta's Vista-blocking antibody KVA12123 and a preclinical CD27-targeted therapy.The merged company aims to address primary and acquired resistance to current cancer immunotherapies.Tuhura stockholders approved key measures, including increasing authorized shares to 200 million and reincorporating the company in Delaware.&nbsp;Kineta stockholders also approved the merger terms at a separate special meeting.The transaction is expected to close soon, subject to the fulfillment or waiver of remaining conditions.&nbsp;Tuhura is planning to initiate a randomized Phase 3 trial of IFx-2.0 in combination with Keytruda (pembrolizumab) as first-line therapy for advanced or metastatic Merkel Cell Carcinoma.Kineta's Vista therapy, KVA12123, had previously entered Phase 1/2 trials for solid tumors but was paused in 2024 amid a corporate restructuring that included job cuts to reduce expenses and preserve cash.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.One user said Tuhura could trade above $10 and reach valuations higher than $15.&nbsp;<stembedurl>https://stocktwits.com/Aburose/message/618740816</stembedurl>Another user noted that the stock had consistently moved higher near the close in recent sessions.<stembedurl>https://stocktwits.com/LifesGood/message/618742837</stembedurl>Tuhura’s stock has declined 38.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Tuhura Biosciences Surges After-Hours As Investors Bet On Kineta Merger, Cancer Drug Pipeline

The merger brings together two biotech firms aiming to tackle immune resistance in cancer, with plans to advance programs targeting Merkel Cell Carcinoma.

Equity

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL.

TuHURA Biosciences Inc.

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

HURA
TuHURA Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HURA News

HURATuHURA Biosciences Inc.